 Andres Henao Martinez
Concepts (481)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chagas Disease | 13 | 2023 | 35 | 7.510 |
Why?
| | Chagas Cardiomyopathy | 7 | 2023 | 22 | 4.550 |
Why?
| | Meningitis, Cryptococcal | 8 | 2024 | 28 | 3.820 |
Why?
| | Cryptococcosis | 6 | 2023 | 23 | 3.600 |
Why?
| | Opportunistic Infections | 4 | 2024 | 48 | 2.720 |
Why?
| | Trypanosoma cruzi | 6 | 2023 | 23 | 2.520 |
Why?
| | Cryptococcus neoformans | 4 | 2024 | 18 | 1.940 |
Why?
| | Invasive Pulmonary Aspergillosis | 2 | 2023 | 3 | 1.790 |
Why?
| | HIV Infections | 10 | 2024 | 2588 | 1.730 |
Why?
| | Travel | 6 | 2021 | 131 | 1.660 |
Why?
| | Strongyloidiasis | 2 | 2024 | 4 | 1.490 |
Why?
| | Cryptococcus | 2 | 2024 | 8 | 1.480 |
Why?
| | Immunocompromised Host | 6 | 2024 | 207 | 1.380 |
Why?
| | Stroke, Lacunar | 2 | 2019 | 4 | 1.310 |
Why?
| | Transients and Migrants | 3 | 2023 | 22 | 1.210 |
Why?
| | Tuberculosis | 2 | 2022 | 279 | 1.210 |
Why?
| | Candidemia | 2 | 2024 | 9 | 1.200 |
Why?
| | Hospitalization | 7 | 2024 | 1960 | 1.200 |
Why?
| | Humans | 102 | 2024 | 125131 | 1.170 |
Why?
| | Cardiomyopathies | 2 | 2021 | 314 | 1.160 |
Why?
| | Yellow Fever | 3 | 2022 | 7 | 1.120 |
Why?
| | Bacteremia | 5 | 2023 | 166 | 1.100 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2019 | 160 | 1.060 |
Why?
| | Candida | 2 | 2024 | 37 | 1.030 |
Why?
| | Central Nervous System Neoplasms | 2 | 2018 | 130 | 1.010 |
Why?
| | Glucocorticoids | 3 | 2024 | 554 | 1.010 |
Why?
| | Antifungal Agents | 8 | 2023 | 140 | 1.000 |
Why?
| | Parasitemia | 2 | 2015 | 9 | 0.950 |
Why?
| | Pneumocystis | 1 | 2024 | 11 | 0.940 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2024 | 34 | 0.920 |
Why?
| | Pulmonary Aspergillosis | 1 | 2023 | 3 | 0.900 |
Why?
| | Nitroimidazoles | 1 | 2023 | 7 | 0.900 |
Why?
| | Adult | 35 | 2024 | 33167 | 0.900 |
Why?
| | Myocarditis | 2 | 2016 | 99 | 0.870 |
Why?
| | Anemia, Aplastic | 1 | 2023 | 30 | 0.870 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2024 | 117 | 0.860 |
Why?
| | Pneumonia, Viral | 7 | 2020 | 360 | 0.850 |
Why?
| | Coronavirus Infections | 7 | 2020 | 347 | 0.850 |
Why?
| | Risk Factors | 14 | 2024 | 9549 | 0.850 |
Why?
| | Enterobacteriaceae Infections | 2 | 2013 | 32 | 0.840 |
Why?
| | Zoonoses | 2 | 2024 | 25 | 0.830 |
Why?
| | Male | 43 | 2024 | 60792 | 0.800 |
Why?
| | Anti-Bacterial Agents | 8 | 2023 | 1559 | 0.780 |
Why?
| | Antigens, Fungal | 2 | 2024 | 28 | 0.780 |
Why?
| | Neglected Diseases | 1 | 2020 | 4 | 0.750 |
Why?
| | Mycobacterium Infections | 2 | 2018 | 65 | 0.730 |
Why?
| | Hepatitis | 1 | 2020 | 48 | 0.720 |
Why?
| | Hantavirus Pulmonary Syndrome | 1 | 2020 | 3 | 0.700 |
Why?
| | Heart Aneurysm | 1 | 2019 | 10 | 0.690 |
Why?
| | Epidemics | 1 | 2020 | 76 | 0.680 |
Why?
| | United States | 19 | 2024 | 13613 | 0.670 |
Why?
| | Massive Hepatic Necrosis | 1 | 2019 | 3 | 0.670 |
Why?
| | Aneurysm, False | 1 | 2019 | 47 | 0.660 |
Why?
| | Hepatitis A | 1 | 2019 | 28 | 0.660 |
Why?
| | Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 2 | 0.650 |
Why?
| | Sarcoma, Myeloid | 1 | 2018 | 4 | 0.640 |
Why?
| | Hematoma, Subdural | 1 | 2018 | 20 | 0.640 |
Why?
| | Neisseria gonorrhoeae | 1 | 2019 | 28 | 0.640 |
Why?
| | Middle Aged | 22 | 2024 | 29112 | 0.620 |
Why?
| | Skin | 3 | 2022 | 698 | 0.620 |
Why?
| | Dyspnea | 1 | 2019 | 220 | 0.610 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 37 | 0.610 |
Why?
| | Chromoblastomycosis | 1 | 2017 | 2 | 0.610 |
Why?
| | Malaria, Falciparum | 1 | 2018 | 33 | 0.600 |
Why?
| | Fever | 2 | 2020 | 294 | 0.600 |
Why?
| | Population Groups | 1 | 2018 | 57 | 0.600 |
Why?
| | Hand Dermatoses | 1 | 2017 | 9 | 0.600 |
Why?
| | Renal Insufficiency | 1 | 2020 | 155 | 0.600 |
Why?
| | Gonorrhea | 1 | 2019 | 72 | 0.600 |
Why?
| | Delayed Diagnosis | 1 | 2018 | 85 | 0.590 |
Why?
| | Meningioma | 1 | 2018 | 84 | 0.580 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 92 | 0.580 |
Why?
| | Osteomyelitis | 1 | 2019 | 111 | 0.580 |
Why?
| | Abscess | 1 | 2018 | 75 | 0.580 |
Why?
| | Retrospective Studies | 12 | 2024 | 13708 | 0.570 |
Why?
| | Medically Uninsured | 1 | 2018 | 135 | 0.570 |
Why?
| | Heart Failure | 2 | 2022 | 2154 | 0.570 |
Why?
| | Female | 34 | 2024 | 64889 | 0.570 |
Why?
| | Milk | 1 | 2018 | 133 | 0.560 |
Why?
| | Prisons | 4 | 2021 | 57 | 0.560 |
Why?
| | Poliomyelitis | 3 | 2022 | 27 | 0.560 |
Why?
| | Pandemics | 10 | 2023 | 1434 | 0.560 |
Why?
| | Latin America | 6 | 2022 | 72 | 0.560 |
Why?
| | Trichuriasis | 1 | 2016 | 4 | 0.540 |
Why?
| | Pregnancy Complications, Parasitic | 1 | 2016 | 10 | 0.540 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2016 | 18 | 0.540 |
Why?
| | Lymphocytosis | 1 | 2016 | 10 | 0.540 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2016 | 12 | 0.540 |
Why?
| | Enterobacteriaceae | 2 | 2013 | 33 | 0.540 |
Why?
| | Parotid Neoplasms | 1 | 2016 | 16 | 0.530 |
Why?
| | Occupational Diseases | 1 | 2017 | 147 | 0.520 |
Why?
| | Diphyllobothriasis | 1 | 2015 | 2 | 0.520 |
Why?
| | Diphyllobothrium | 1 | 2015 | 2 | 0.520 |
Why?
| | Plasmablastic Lymphoma | 1 | 2015 | 6 | 0.520 |
Why?
| | Colombia | 4 | 2020 | 43 | 0.520 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2018 | 183 | 0.520 |
Why?
| | Insect Vectors | 1 | 2015 | 30 | 0.510 |
Why?
| | Plasma Cells | 1 | 2015 | 60 | 0.500 |
Why?
| | Gamma Rays | 1 | 2015 | 56 | 0.500 |
Why?
| | Transplants | 1 | 2015 | 38 | 0.500 |
Why?
| | Lymphoma | 1 | 2016 | 185 | 0.490 |
Why?
| | Anemia | 1 | 2016 | 162 | 0.480 |
Why?
| | Bone Marrow | 1 | 2016 | 259 | 0.480 |
Why?
| | Heart Ventricles | 1 | 2019 | 763 | 0.470 |
Why?
| | Thrombocytopenia | 1 | 2016 | 188 | 0.460 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2023 | 437 | 0.460 |
Why?
| | Environmental Exposure | 1 | 2018 | 424 | 0.460 |
Why?
| | Transplant Recipients | 1 | 2015 | 150 | 0.450 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2023 | 195 | 0.430 |
Why?
| | Myocardial Contraction | 1 | 2015 | 339 | 0.430 |
Why?
| | Lymphoma, Primary Effusion | 1 | 2013 | 3 | 0.430 |
Why?
| | Thrombocytosis | 1 | 2013 | 8 | 0.430 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2013 | 13 | 0.430 |
Why?
| | Research | 1 | 2016 | 440 | 0.430 |
Why?
| | Betacoronavirus | 6 | 2020 | 263 | 0.420 |
Why?
| | Antigens, Protozoan | 1 | 2012 | 20 | 0.420 |
Why?
| | Acinetobacter Infections | 1 | 2012 | 10 | 0.410 |
Why?
| | Acinetobacter | 1 | 2012 | 14 | 0.410 |
Why?
| | Proctitis | 1 | 2012 | 5 | 0.410 |
Why?
| | H-2 Antigens | 1 | 2012 | 111 | 0.410 |
Why?
| | Herpes Genitalis | 1 | 2012 | 19 | 0.410 |
Why?
| | Herpesvirus 2, Human | 1 | 2012 | 31 | 0.400 |
Why?
| | Healthcare Disparities | 3 | 2024 | 515 | 0.400 |
Why?
| | Cellulitis | 1 | 2012 | 48 | 0.400 |
Why?
| | Herpesvirus 8, Human | 1 | 2013 | 80 | 0.400 |
Why?
| | Aged | 11 | 2024 | 20859 | 0.400 |
Why?
| | Isoxazoles | 1 | 2012 | 57 | 0.390 |
Why?
| | Yellow Fever Vaccine | 2 | 2022 | 6 | 0.390 |
Why?
| | Severe Dengue | 1 | 2011 | 9 | 0.390 |
Why?
| | Acyclovir | 1 | 2012 | 103 | 0.390 |
Why?
| | Animals | 15 | 2024 | 34345 | 0.380 |
Why?
| | Emigration and Immigration | 2 | 2022 | 52 | 0.380 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 147 | 0.380 |
Why?
| | Treatment Outcome | 11 | 2024 | 9790 | 0.380 |
Why?
| | B-Lymphocytes | 1 | 2016 | 781 | 0.370 |
Why?
| | Poliovirus | 2 | 2022 | 77 | 0.360 |
Why?
| | Pancreatitis | 1 | 2011 | 111 | 0.360 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3309 | 0.360 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2236 | 0.350 |
Why?
| | Moraxellaceae Infections | 1 | 2009 | 3 | 0.340 |
Why?
| | Repressor Proteins | 1 | 2013 | 383 | 0.340 |
Why?
| | Moraxella | 1 | 2009 | 5 | 0.340 |
Why?
| | Lung Diseases | 2 | 2018 | 768 | 0.330 |
Why?
| | Acute Lung Injury | 1 | 2013 | 319 | 0.330 |
Why?
| | Lupus Nephritis | 1 | 2009 | 57 | 0.330 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1080 | 0.330 |
Why?
| | Fluconazole | 3 | 2023 | 17 | 0.330 |
Why?
| | Aged, 80 and over | 5 | 2024 | 6936 | 0.320 |
Why?
| | Arthritis, Infectious | 1 | 2009 | 53 | 0.320 |
Why?
| | Staphylococcal Infections | 3 | 2023 | 347 | 0.310 |
Why?
| | Presenilin-1 | 1 | 2008 | 28 | 0.310 |
Why?
| | Immunoglobulin G | 3 | 2023 | 808 | 0.310 |
Why?
| | Fatal Outcome | 2 | 2019 | 299 | 0.300 |
Why?
| | Engineering | 1 | 2018 | 26 | 0.300 |
Why?
| | Pulmonary Emphysema | 1 | 2011 | 362 | 0.300 |
Why?
| | Social Responsibility | 1 | 2018 | 51 | 0.290 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1442 | 0.290 |
Why?
| | Echinocandins | 2 | 2023 | 9 | 0.280 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2018 | 73 | 0.280 |
Why?
| | Mycobacterium | 2 | 2018 | 105 | 0.280 |
Why?
| | Public Health | 3 | 2020 | 493 | 0.270 |
Why?
| | Antiviral Agents | 1 | 2012 | 673 | 0.270 |
Why?
| | Attitude | 1 | 2018 | 248 | 0.260 |
Why?
| | Acute Kidney Injury | 1 | 2013 | 727 | 0.260 |
Why?
| | HIV | 2 | 2018 | 218 | 0.260 |
Why?
| | Young Adult | 8 | 2024 | 11384 | 0.260 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1006 | 0.260 |
Why?
| | Sepsis | 2 | 2022 | 563 | 0.260 |
Why?
| | Propensity Score | 2 | 2023 | 257 | 0.250 |
Why?
| | Shock, Septic | 2 | 2021 | 217 | 0.250 |
Why?
| | Electrocardiography | 2 | 2019 | 637 | 0.250 |
Why?
| | Candida tropicalis | 1 | 2024 | 7 | 0.250 |
Why?
| | Insect Bites and Stings | 1 | 2024 | 12 | 0.240 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 669 | 0.240 |
Why?
| | Strongyloides stercoralis | 1 | 2024 | 2 | 0.240 |
Why?
| | Colorado | 3 | 2020 | 4471 | 0.230 |
Why?
| | Teicoplanin | 2 | 2023 | 17 | 0.230 |
Why?
| | Alanine | 1 | 2024 | 104 | 0.230 |
Why?
| | Peru | 2 | 2024 | 61 | 0.230 |
Why?
| | Toxoplasmosis | 1 | 2023 | 32 | 0.220 |
Why?
| | Toxoplasma | 1 | 2023 | 34 | 0.220 |
Why?
| | World Health Organization | 2 | 2021 | 115 | 0.220 |
Why?
| | Meningoencephalitis | 1 | 2023 | 25 | 0.220 |
Why?
| | Voriconazole | 1 | 2023 | 24 | 0.220 |
Why?
| | Pyridones | 1 | 2024 | 120 | 0.220 |
Why?
| | Rabies | 1 | 2022 | 1 | 0.210 |
Why?
| | Rabies Vaccines | 1 | 2022 | 1 | 0.210 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 1992 | 0.210 |
Why?
| | Students | 1 | 2018 | 552 | 0.210 |
Why?
| | Antiparasitic Agents | 1 | 2022 | 3 | 0.210 |
Why?
| | Pregnancy | 4 | 2024 | 5922 | 0.210 |
Why?
| | Tenofovir | 1 | 2024 | 214 | 0.210 |
Why?
| | Glycopeptides | 1 | 2023 | 63 | 0.210 |
Why?
| | Prognosis | 3 | 2022 | 3616 | 0.210 |
Why?
| | Dog Diseases | 1 | 2022 | 46 | 0.200 |
Why?
| | Tomography, X-Ray Computed | 4 | 2019 | 2539 | 0.200 |
Why?
| | Americas | 1 | 2022 | 23 | 0.200 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1006 | 0.200 |
Why?
| | Alzheimer Disease | 1 | 2008 | 529 | 0.200 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 879 | 0.200 |
Why?
| | Disease Notification | 1 | 2022 | 17 | 0.200 |
Why?
| | Italy | 1 | 2022 | 94 | 0.200 |
Why?
| | Travel Medicine | 2 | 2020 | 5 | 0.200 |
Why?
| | Staphylococcal Skin Infections | 2 | 2012 | 30 | 0.200 |
Why?
| | Leprosy | 1 | 2021 | 13 | 0.200 |
Why?
| | Rural Population | 2 | 2022 | 497 | 0.190 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1191 | 0.190 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2023 | 232 | 0.190 |
Why?
| | Population Dynamics | 1 | 2022 | 143 | 0.190 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 229 | 0.190 |
Why?
| | Leishmania guyanensis | 1 | 2020 | 1 | 0.180 |
Why?
| | Case-Control Studies | 3 | 2018 | 3326 | 0.180 |
Why?
| | Weight Gain | 1 | 2024 | 517 | 0.180 |
Why?
| | Leishmaniasis, Cutaneous | 1 | 2020 | 9 | 0.180 |
Why?
| | Phosphorylcholine | 1 | 2020 | 18 | 0.180 |
Why?
| | Antiprotozoal Agents | 1 | 2020 | 12 | 0.180 |
Why?
| | Pericarditis | 1 | 2020 | 9 | 0.180 |
Why?
| | Personal Protective Equipment | 1 | 2021 | 55 | 0.180 |
Why?
| | Anti-Inflammatory Agents | 1 | 2024 | 471 | 0.180 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 35 | 0.180 |
Why?
| | Developing Countries | 1 | 2022 | 269 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 1198 | 0.180 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 28 | 0.180 |
Why?
| | Africa | 1 | 2020 | 103 | 0.170 |
Why?
| | Immunization, Secondary | 1 | 2020 | 86 | 0.170 |
Why?
| | Late Onset Disorders | 1 | 2019 | 2 | 0.170 |
Why?
| | Immunosuppressive Agents | 1 | 2024 | 693 | 0.170 |
Why?
| | Bolivia | 1 | 2019 | 64 | 0.170 |
Why?
| | Proteinuria | 1 | 2020 | 100 | 0.170 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2020 | 68 | 0.170 |
Why?
| | Infection Control | 1 | 2021 | 144 | 0.170 |
Why?
| | Prospective Studies | 4 | 2023 | 6818 | 0.170 |
Why?
| | Sexual and Gender Minorities | 1 | 2022 | 172 | 0.170 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 10 | 0.160 |
Why?
| | Medical Errors | 1 | 2020 | 100 | 0.160 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 97 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2382 | 0.160 |
Why?
| | Amphotericin B | 1 | 2019 | 33 | 0.160 |
Why?
| | Cryptococcus gattii | 1 | 2018 | 1 | 0.160 |
Why?
| | Vulnerable Populations | 1 | 2020 | 156 | 0.160 |
Why?
| | Dermatitis | 1 | 2018 | 18 | 0.160 |
Why?
| | Acute Disease | 2 | 2012 | 1016 | 0.160 |
Why?
| | Echocardiography | 2 | 2020 | 609 | 0.160 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 231 | 0.160 |
Why?
| | Stroke Volume | 1 | 2021 | 570 | 0.160 |
Why?
| | Prisoners | 1 | 2020 | 96 | 0.160 |
Why?
| | Speech Disorders | 1 | 2018 | 36 | 0.160 |
Why?
| | Neoplasms | 1 | 2013 | 2340 | 0.160 |
Why?
| | Computed Tomography Angiography | 1 | 2019 | 112 | 0.160 |
Why?
| | Emigrants and Immigrants | 1 | 2020 | 117 | 0.160 |
Why?
| | Africa, Western | 1 | 2018 | 17 | 0.160 |
Why?
| | Sex Factors | 1 | 2024 | 1901 | 0.160 |
Why?
| | Administration, Intravenous | 1 | 2019 | 148 | 0.150 |
Why?
| | Raw Foods | 1 | 2018 | 2 | 0.150 |
Why?
| | California | 1 | 2019 | 385 | 0.150 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 511 | 0.150 |
Why?
| | Itraconazole | 1 | 2017 | 7 | 0.150 |
Why?
| | Respiration, Artificial | 1 | 2022 | 595 | 0.150 |
Why?
| | Time Factors | 2 | 2019 | 6780 | 0.150 |
Why?
| | Administration, Oral | 2 | 2020 | 785 | 0.150 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2669 | 0.150 |
Why?
| | Food Microbiology | 1 | 2018 | 59 | 0.150 |
Why?
| | Georgia | 1 | 2017 | 61 | 0.150 |
Why?
| | Arrhythmias, Cardiac | 1 | 2020 | 313 | 0.150 |
Why?
| | Cytokines | 2 | 2022 | 1927 | 0.150 |
Why?
| | Hyponatremia | 1 | 2018 | 46 | 0.140 |
Why?
| | Antibodies, Viral | 1 | 2020 | 561 | 0.140 |
Why?
| | Disability Evaluation | 1 | 2019 | 290 | 0.140 |
Why?
| | Patient Safety | 1 | 2020 | 306 | 0.140 |
Why?
| | Farmers | 1 | 2017 | 61 | 0.140 |
Why?
| | Research Design | 2 | 2021 | 1035 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 716 | 0.140 |
Why?
| | Mebendazole | 1 | 2016 | 2 | 0.140 |
Why?
| | Strongyloides | 1 | 2016 | 2 | 0.140 |
Why?
| | Trichuris | 1 | 2016 | 3 | 0.140 |
Why?
| | Albendazole | 1 | 2016 | 5 | 0.140 |
Why?
| | Ivermectin | 1 | 2016 | 10 | 0.140 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1183 | 0.130 |
Why?
| | Vaccination | 2 | 2022 | 1241 | 0.130 |
Why?
| | Interleukin-6 | 1 | 2020 | 710 | 0.130 |
Why?
| | Pharmacists | 1 | 2019 | 248 | 0.130 |
Why?
| | Brain | 1 | 2008 | 2639 | 0.130 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 247 | 0.130 |
Why?
| | Hematocrit | 1 | 2016 | 97 | 0.130 |
Why?
| | Praziquantel | 1 | 2015 | 6 | 0.130 |
Why?
| | Hospitals, University | 1 | 2016 | 193 | 0.130 |
Why?
| | Arachis | 1 | 2017 | 151 | 0.130 |
Why?
| | Anthelmintics | 1 | 2015 | 9 | 0.130 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 745 | 0.130 |
Why?
| | Disease Outbreaks | 3 | 2023 | 334 | 0.130 |
Why?
| | Clone Cells | 1 | 2016 | 251 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1431 | 0.130 |
Why?
| | Mental Disorders | 1 | 2023 | 976 | 0.130 |
Why?
| | Recurrence | 1 | 2018 | 1011 | 0.120 |
Why?
| | Lipids | 1 | 2019 | 629 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2018 | 447 | 0.120 |
Why?
| | Herpesvirus 4, Human | 1 | 2015 | 129 | 0.120 |
Why?
| | Migraine Disorders | 1 | 2016 | 95 | 0.120 |
Why?
| | Genotype | 2 | 2012 | 1960 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 126 | 0.120 |
Why?
| | Health Care Costs | 1 | 2018 | 415 | 0.120 |
Why?
| | Frontal Lobe | 1 | 2015 | 152 | 0.120 |
Why?
| | Hearing Loss | 1 | 2018 | 195 | 0.120 |
Why?
| | Hemoglobins | 1 | 2016 | 299 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 524 | 0.120 |
Why?
| | Heart Transplantation | 1 | 2020 | 689 | 0.120 |
Why?
| | Biopsy | 2 | 2020 | 1093 | 0.120 |
Why?
| | Health Status Disparities | 3 | 2020 | 222 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1561 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2021 | 925 | 0.110 |
Why?
| | Parasite Load | 1 | 2013 | 8 | 0.110 |
Why?
| | Feces | 1 | 2015 | 402 | 0.110 |
Why?
| | Disease Progression | 2 | 2012 | 2577 | 0.110 |
Why?
| | Mycoplasma hominis | 1 | 2012 | 4 | 0.110 |
Why?
| | Mycoplasma Infections | 1 | 2012 | 14 | 0.110 |
Why?
| | APACHE | 1 | 2013 | 65 | 0.110 |
Why?
| | Klebsiella Infections | 1 | 2013 | 25 | 0.110 |
Why?
| | Intestines | 1 | 2016 | 337 | 0.110 |
Why?
| | Platelet Count | 1 | 2013 | 89 | 0.110 |
Why?
| | Child | 6 | 2023 | 20014 | 0.110 |
Why?
| | Anti-HIV Agents | 2 | 2024 | 701 | 0.100 |
Why?
| | Molecular Typing | 1 | 2012 | 19 | 0.100 |
Why?
| | Clindamycin | 1 | 2012 | 12 | 0.100 |
Why?
| | Syncope | 1 | 2013 | 40 | 0.100 |
Why?
| | Serratia Infections | 1 | 2012 | 6 | 0.100 |
Why?
| | Logistic Models | 1 | 2018 | 2040 | 0.100 |
Why?
| | Serratia marcescens | 1 | 2012 | 12 | 0.100 |
Why?
| | Comorbidity | 2 | 2022 | 1635 | 0.100 |
Why?
| | Linkage Disequilibrium | 1 | 2013 | 288 | 0.100 |
Why?
| | Central America | 2 | 2023 | 27 | 0.100 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2013 | 78 | 0.100 |
Why?
| | Thoracic Vertebrae | 1 | 2012 | 73 | 0.100 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 1233 | 0.100 |
Why?
| | Disease Eradication | 2 | 2022 | 4 | 0.100 |
Why?
| | Hedgehog Proteins | 1 | 2013 | 176 | 0.100 |
Why?
| | Viral Load | 2 | 2024 | 426 | 0.100 |
Why?
| | Blister | 1 | 2011 | 44 | 0.100 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2011 | 38 | 0.100 |
Why?
| | Microscopy | 1 | 2013 | 136 | 0.100 |
Why?
| | Drug Resistance, Viral | 1 | 2012 | 100 | 0.100 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2015 | 506 | 0.100 |
Why?
| | Poliovirus Vaccine, Oral | 2 | 2022 | 19 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2578 | 0.100 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 161 | 0.100 |
Why?
| | Soft Tissue Infections | 1 | 2011 | 29 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2488 | 0.090 |
Why?
| | Venezuela | 2 | 2021 | 7 | 0.090 |
Why?
| | Coinfection | 1 | 2012 | 123 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2012 | 86 | 0.090 |
Why?
| | Myocardium | 1 | 2016 | 992 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2011 | 117 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 4854 | 0.090 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 148 | 0.090 |
Why?
| | Urinary Tract Infections | 1 | 2012 | 145 | 0.090 |
Why?
| | Cross Infection | 1 | 2013 | 220 | 0.090 |
Why?
| | Cohort Studies | 3 | 2022 | 5348 | 0.090 |
Why?
| | Mice | 3 | 2023 | 15984 | 0.090 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2013 | 236 | 0.090 |
Why?
| | Gene Expression | 1 | 2015 | 1528 | 0.090 |
Why?
| | Surgical Wound Infection | 1 | 2012 | 263 | 0.090 |
Why?
| | Penicillanic Acid | 1 | 2009 | 4 | 0.090 |
Why?
| | Piperacillin | 1 | 2009 | 8 | 0.090 |
Why?
| | Bacterial Typing Techniques | 1 | 2009 | 43 | 0.080 |
Why?
| | Debridement | 1 | 2009 | 92 | 0.080 |
Why?
| | Spinal Cord Injuries | 1 | 2012 | 184 | 0.080 |
Why?
| | Hypertension | 1 | 2018 | 1257 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 244 | 0.080 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 391 | 0.080 |
Why?
| | Needs Assessment | 2 | 2021 | 358 | 0.080 |
Why?
| | Mortality | 2 | 2021 | 327 | 0.080 |
Why?
| | Genes, Dominant | 1 | 2008 | 98 | 0.080 |
Why?
| | Socialization | 1 | 2018 | 24 | 0.080 |
Why?
| | Chromosome Disorders | 1 | 2008 | 39 | 0.080 |
Why?
| | Global Health | 2 | 2020 | 350 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 279 | 0.070 |
Why?
| | Intensive Care Units | 2 | 2023 | 663 | 0.070 |
Why?
| | Point Mutation | 1 | 2008 | 236 | 0.070 |
Why?
| | DNA Mutational Analysis | 1 | 2008 | 394 | 0.070 |
Why?
| | Genetic Markers | 1 | 2008 | 368 | 0.070 |
Why?
| | Pedigree | 1 | 2008 | 506 | 0.070 |
Why?
| | Gene Frequency | 1 | 2008 | 528 | 0.070 |
Why?
| | Chronic Disease | 1 | 2012 | 1684 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 523 | 0.070 |
Why?
| | Amyloid beta-Peptides | 1 | 2008 | 201 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2012 | 840 | 0.060 |
Why?
| | Genetic Testing | 1 | 2008 | 401 | 0.060 |
Why?
| | Interviews as Topic | 1 | 2018 | 649 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2492 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2135 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 5102 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 965 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2012 | 833 | 0.060 |
Why?
| | Registries | 1 | 2013 | 2050 | 0.060 |
Why?
| | Moths | 1 | 2024 | 37 | 0.060 |
Why?
| | Aminobutyrates | 1 | 2024 | 34 | 0.060 |
Why?
| | Drug Substitution | 1 | 2024 | 48 | 0.060 |
Why?
| | Antivenins | 1 | 2024 | 60 | 0.060 |
Why?
| | Antibodies, Protozoan | 1 | 2023 | 30 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2008 | 713 | 0.060 |
Why?
| | Acetazolamide | 1 | 2023 | 32 | 0.060 |
Why?
| | Adolescent | 4 | 2023 | 19411 | 0.060 |
Why?
| | Human Rights | 1 | 2023 | 16 | 0.060 |
Why?
| | Seroepidemiologic Studies | 1 | 2023 | 154 | 0.060 |
Why?
| | HIV Integrase Inhibitors | 1 | 2024 | 63 | 0.050 |
Why?
| | Panama | 1 | 2022 | 10 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 134 | 0.050 |
Why?
| | Yellow fever virus | 1 | 2022 | 3 | 0.050 |
Why?
| | Medicine, Traditional | 1 | 2022 | 25 | 0.050 |
Why?
| | Monkeypox virus | 1 | 2022 | 12 | 0.050 |
Why?
| | Standard of Care | 1 | 2023 | 64 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2012 | 3823 | 0.050 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2022 | 22 | 0.050 |
Why?
| | Adenine | 1 | 2024 | 229 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 1 | 2023 | 273 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2023 | 253 | 0.050 |
Why?
| | Mexico | 1 | 2022 | 170 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2806 | 0.050 |
Why?
| | Vancomycin | 1 | 2023 | 77 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2023 | 310 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 5061 | 0.050 |
Why?
| | Cuba | 1 | 2021 | 12 | 0.050 |
Why?
| | Mycobacterium leprae | 1 | 2021 | 7 | 0.050 |
Why?
| | Cameroon | 1 | 2021 | 11 | 0.050 |
Why?
| | Contact Tracing | 1 | 2021 | 27 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2009 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2022 | 214 | 0.050 |
Why?
| | Dogs | 1 | 2022 | 394 | 0.050 |
Why?
| | Curriculum | 1 | 2018 | 943 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2022 | 184 | 0.050 |
Why?
| | Minority Health | 1 | 2021 | 19 | 0.050 |
Why?
| | Inflammation | 2 | 2022 | 2612 | 0.050 |
Why?
| | Cardiovascular Infections | 1 | 2020 | 2 | 0.050 |
Why?
| | Pericardiocentesis | 1 | 2020 | 10 | 0.050 |
Why?
| | Minority Groups | 1 | 2022 | 251 | 0.050 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2024 | 301 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 173 | 0.050 |
Why?
| | History, 17th Century | 1 | 2020 | 19 | 0.050 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.040 |
Why?
| | Social Justice | 1 | 2021 | 66 | 0.040 |
Why?
| | Hemorrhage | 1 | 2024 | 673 | 0.040 |
Why?
| | Network Meta-Analysis | 1 | 2020 | 17 | 0.040 |
Why?
| | Crowding | 1 | 2020 | 40 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 347 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 4809 | 0.040 |
Why?
| | Policy Making | 1 | 2020 | 90 | 0.040 |
Why?
| | Brazil | 1 | 2020 | 111 | 0.040 |
Why?
| | Catheter-Related Infections | 1 | 2020 | 65 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2020 | 74 | 0.040 |
Why?
| | History, 21st Century | 1 | 2020 | 181 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2023 | 400 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2022 | 147 | 0.040 |
Why?
| | Frail Elderly | 1 | 2020 | 112 | 0.040 |
Why?
| | Cough | 1 | 2020 | 108 | 0.040 |
Why?
| | History, 20th Century | 1 | 2020 | 290 | 0.040 |
Why?
| | Southeastern United States | 1 | 2018 | 33 | 0.040 |
Why?
| | Nursing Homes | 1 | 2020 | 150 | 0.040 |
Why?
| | HIV-1 | 1 | 2024 | 787 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2020 | 133 | 0.040 |
Why?
| | Drug Compounding | 1 | 2019 | 91 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2020 | 188 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2020 | 228 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 365 | 0.040 |
Why?
| | Residence Characteristics | 1 | 2020 | 317 | 0.040 |
Why?
| | Organ Transplantation | 1 | 2020 | 170 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1042 | 0.040 |
Why?
| | Risk | 1 | 2020 | 896 | 0.040 |
Why?
| | Urban Population | 1 | 2020 | 433 | 0.040 |
Why?
| | Critical Illness | 1 | 2023 | 719 | 0.040 |
Why?
| | Occupational Exposure | 1 | 2020 | 314 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 654 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 585 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 666 | 0.030 |
Why?
| | Mass Screening | 1 | 2022 | 1119 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3471 | 0.030 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2012 | 17 | 0.030 |
Why?
| | Molecular Epidemiology | 1 | 2012 | 74 | 0.030 |
Why?
| | Risk Assessment | 1 | 2020 | 3274 | 0.020 |
Why?
| | Infant | 1 | 2021 | 8625 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 9938 | 0.020 |
Why?
| | Lung | 1 | 2020 | 3865 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2026 | 0.020 |
Why?
|
|
Henao Martinez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|